Drugs / AK146D1
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07067567 | Aug 2025 → Nov 2026 expected | cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1 | NCT06929663 | Jul 2025 → Nov 2026 expected | cancer | Akeso | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07669779 | Jul 2026 → Aug 2027 expected | non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT07636772 | Jun 2026 → Aug 2028 expected | urothelial carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07591090 | Jun 2026 → Sep 2027 expected | female breast carcinoma | Akeso | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-10 | Akeso | IO2.0+ADC2.0疗法|康方Trop2/Nectin4双抗ADC(AK146D1)联合依沃西治疗乳腺癌II期研究首例入组 akesobio.com ↗ |
| 2026-07-20 | Akeso | IO2.0+ADC2.0 战略| 康方Trop2/Nectin4双抗ADC(AK146D1)联合依沃西治疗NSCLC的 II 期研究首例入组 akesobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK146D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07636772 ↗ |
| Known as | AK146D1 for injection | “AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate” NCT06929663 ↗ |
| Route | Intravenous | “Participants in this group will receive AK146D1 combined with AK112 as i.v. infusion.” NCT07591090 ↗ |